IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million
December 15, 2020 08:05 ET | Idera Pharmaceuticals, Inc.
EXTON, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020
September 15, 2020 07:18 ET | Idera Pharmaceuticals, Inc.
Final data from ILLUMINATE-204 trial in advanced melanoma and final results from ILLUMINATE-101 trial in refractory solid tumors to be presentedAbbVie to present a trial-in-progress poster of ABBV-368...
aad.jpg
How To Prevent And Treat Common Summer Rashes; American Academy of Dermatology
August 11, 2020 14:30 ET | American Academy of Dermatology
ROSEMONT, Ill., Aug. 11, 2020 (GLOBE NEWSWIRE) -- As the coronavirus continues to spread throughout the country, many people may find themselves spending more time outdoors for a much-needed change...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab) Combination in Melanoma
July 31, 2020 02:00 ET | BioNTech SE
BioNTech and Regeneron plan to jointly conduct a randomized Phase 2 study combining BNT111 FixVac and Libtayo for the treatment of melanoma that has progressed after prior PD-1 blockadeCombines two...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
BioNTech gibt Kollaboration mit Regeneron zur Entwicklung einer Melanom-Kombinationstherapie aus FixVac und Libtayo® (Cemiplimab) bekannt
July 31, 2020 02:00 ET | BioNTech SE
BioNTech und Regeneron planen die gemeinsame Durchführung einer randomisierten Phase-2-Studie mit einer Kombination aus FixVac BNT111 und Libtayo für die Behandlung von maligem Melanom (schwarzer...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
BioNTech Publishes Data from mRNA-based BNT111 FixVac Melanoma Trial in Nature
July 30, 2020 03:00 ET | BioNTech SE
Preliminary Phase 1 results from Lipo-MERIT trial with data from 89 patients highlight favorable tolerability profile of BNT111 in advanced melanoma patientsEfficacy analysis in a subset of 42...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
BioNTech veröffentlicht Daten aus Studie mit mRNA-basiertem FixVac-Melanom-Programm BNT111 in Nature
July 30, 2020 03:00 ET | BioNTech SE
Vorläufige Phase-1-Ergebnisse der Lipo-MERIT-Studie mit Daten von 89 Patienten zeigen vorteilhaftes Verträglichkeitsprofil für BNT111 in Patienten mit fortgeschrittenem malignem...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million
July 15, 2020 08:05 ET | Idera Pharmaceuticals, Inc.
EXTON, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with institutional investors providing for...
aad.jpg
What to Wear to Protect Your Skin From the Sun; American Academy of Dermatology
June 30, 2020 14:30 ET | American Academy of Dermatology
ROSEMONT, Ill., June 30, 2020 (GLOBE NEWSWIRE) -- Skin cancer is the most common cancer in the U.S., and nearly 20 Americans die from melanoma, the deadliest form of skin cancer, every day. As more...
aad.jpg
Survey: 60% of Americans Say They Have Gotten Sunburned So Badly Their Clothes Were Uncomfortable
May 18, 2020 11:30 ET | American Academy of Dermatology
ROSEMONT, Ill., May 18, 2020 (GLOBE NEWSWIRE) -- Memorial Day — long considered the unofficial start of summer in the U.S. —  is quickly approaching, and dermatologists from the American Academy of...